Acute myeloblastic leukemia
Myelodysplastic syndromes (MDS) are a group of clonal cell disorders characterized by maturation defects, resulting in ineffective hematopoiesis. They often transform to acute myeloblastic leukemia (AML), which is difficult to treat and carries a dismal prognosis. Azacitidine is a hypomethylating ag...
Gespeichert in:
| Veröffentlicht in: | Advances in therapy 2011-03, Vol.28 (Suppl 3), p.10-16 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | Suppl 3 |
| container_start_page | 10 |
| container_title | Advances in therapy |
| container_volume | 28 |
| creator | Molina, Carmen Avellaneda Rodríguez, Maria José Requena de Marcos, Nieves Somolinos Font, Patricia |
| description | Myelodysplastic syndromes (MDS) are a group of clonal cell disorders characterized by maturation defects, resulting in ineffective hematopoiesis. They often transform to acute myeloblastic leukemia (AML), which is difficult to treat and carries a dismal prognosis. Azacitidine is a hypomethylating agent approved for the treatment of patients with MDS, including AML with 20% to 30% bone marrow blasts, according to World Health Organization classification. The three patient cases presented in this paper exemplify the spectrum of antitumor activity and toxicity of azactidine in patients where MDS transformed to AML. |
| doi_str_mv | 10.1007/s12325-010-0109-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_859756376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>859756376</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2583-d3afc5a4ede8e785dcc09ccaf702bddc85a80175ae12fef299d4ecd74f5c2f9e3</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotlYfQATpzlU0l8kkWZZSL1Bwo-AuZJITmTqXmnQWfXtTprp08XMW5zs_nA-ha0ruKSHyIVHGmcCEkkM05idoSlUpcA47RVMiC4oZVx8TdJHShhBGpFDnaMJowWnJ9BTdLNywg3m7h6avGpt2tZs3MHxBW9tLdBZsk-DqOGfo_XH1tnzG69enl-VijR0TimPPbXDCFuBBgVTCO0e0czZIwirvnRJWESqFBcoCBKa1L8B5WQThWNDAZ-hu7N3G_nuAtDNtnRw0je2gH5JRQktRcllmko6ki31KEYLZxrq1cW8oMQclZlRiso5DtOH55vbYPlQt-L-LXwcZYCOQ8qr7hGg2_RC7_PE_rT__Omu3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>859756376</pqid></control><display><type>article</type><title>Acute myeloblastic leukemia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Molina, Carmen Avellaneda ; Rodríguez, Maria José Requena ; de Marcos, Nieves Somolinos ; Font, Patricia</creator><creatorcontrib>Molina, Carmen Avellaneda ; Rodríguez, Maria José Requena ; de Marcos, Nieves Somolinos ; Font, Patricia</creatorcontrib><description>Myelodysplastic syndromes (MDS) are a group of clonal cell disorders characterized by maturation defects, resulting in ineffective hematopoiesis. They often transform to acute myeloblastic leukemia (AML), which is difficult to treat and carries a dismal prognosis. Azacitidine is a hypomethylating agent approved for the treatment of patients with MDS, including AML with 20% to 30% bone marrow blasts, according to World Health Organization classification. The three patient cases presented in this paper exemplify the spectrum of antitumor activity and toxicity of azactidine in patients where MDS transformed to AML.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-010-0109-3</identifier><identifier>PMID: 21431629</identifier><language>eng</language><publisher>Heidelberg: Springer Healthcare Communications</publisher><subject>Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - adverse effects ; Azacitidine - administration & dosage ; Azacitidine - adverse effects ; Bone Marrow - pathology ; Bone Marrow - physiopathology ; Cardiology ; Clinical Cases ; Dose-Response Relationship, Drug ; Drug Hypersensitivity - etiology ; Endocrinology ; Erythema Nodosum - etiology ; Female ; Health technology assessment ; Hematopoiesis - drug effects ; Humans ; Internal Medicine ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - etiology ; Leukemia, Myeloid, Acute - pathology ; Leukemia, Myeloid, Acute - physiopathology ; Lung Diseases, Fungal - etiology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Myelodysplastic Syndromes - complications ; Myelodysplastic Syndromes - drug therapy ; Myelodysplastic Syndromes - pathology ; Myelodysplastic Syndromes - physiopathology ; Oncology ; Pharmacology/Toxicology ; Remission Induction ; Rheumatology</subject><ispartof>Advances in therapy, 2011-03, Vol.28 (Suppl 3), p.10-16</ispartof><rights>Springer Healthcare 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2583-d3afc5a4ede8e785dcc09ccaf702bddc85a80175ae12fef299d4ecd74f5c2f9e3</citedby><cites>FETCH-LOGICAL-c2583-d3afc5a4ede8e785dcc09ccaf702bddc85a80175ae12fef299d4ecd74f5c2f9e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-010-0109-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-010-0109-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21431629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Molina, Carmen Avellaneda</creatorcontrib><creatorcontrib>Rodríguez, Maria José Requena</creatorcontrib><creatorcontrib>de Marcos, Nieves Somolinos</creatorcontrib><creatorcontrib>Font, Patricia</creatorcontrib><title>Acute myeloblastic leukemia</title><title>Advances in therapy</title><addtitle>Adv Therapy</addtitle><addtitle>Adv Ther</addtitle><description>Myelodysplastic syndromes (MDS) are a group of clonal cell disorders characterized by maturation defects, resulting in ineffective hematopoiesis. They often transform to acute myeloblastic leukemia (AML), which is difficult to treat and carries a dismal prognosis. Azacitidine is a hypomethylating agent approved for the treatment of patients with MDS, including AML with 20% to 30% bone marrow blasts, according to World Health Organization classification. The three patient cases presented in this paper exemplify the spectrum of antitumor activity and toxicity of azactidine in patients where MDS transformed to AML.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Azacitidine - administration & dosage</subject><subject>Azacitidine - adverse effects</subject><subject>Bone Marrow - pathology</subject><subject>Bone Marrow - physiopathology</subject><subject>Cardiology</subject><subject>Clinical Cases</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Hypersensitivity - etiology</subject><subject>Endocrinology</subject><subject>Erythema Nodosum - etiology</subject><subject>Female</subject><subject>Health technology assessment</subject><subject>Hematopoiesis - drug effects</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - etiology</subject><subject>Leukemia, Myeloid, Acute - pathology</subject><subject>Leukemia, Myeloid, Acute - physiopathology</subject><subject>Lung Diseases, Fungal - etiology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Myelodysplastic Syndromes - complications</subject><subject>Myelodysplastic Syndromes - drug therapy</subject><subject>Myelodysplastic Syndromes - pathology</subject><subject>Myelodysplastic Syndromes - physiopathology</subject><subject>Oncology</subject><subject>Pharmacology/Toxicology</subject><subject>Remission Induction</subject><subject>Rheumatology</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotlYfQATpzlU0l8kkWZZSL1Bwo-AuZJITmTqXmnQWfXtTprp08XMW5zs_nA-ha0ruKSHyIVHGmcCEkkM05idoSlUpcA47RVMiC4oZVx8TdJHShhBGpFDnaMJowWnJ9BTdLNywg3m7h6avGpt2tZs3MHxBW9tLdBZsk-DqOGfo_XH1tnzG69enl-VijR0TimPPbXDCFuBBgVTCO0e0czZIwirvnRJWESqFBcoCBKa1L8B5WQThWNDAZ-hu7N3G_nuAtDNtnRw0je2gH5JRQktRcllmko6ki31KEYLZxrq1cW8oMQclZlRiso5DtOH55vbYPlQt-L-LXwcZYCOQ8qr7hGg2_RC7_PE_rT__Omu3</recordid><startdate>201103</startdate><enddate>201103</enddate><creator>Molina, Carmen Avellaneda</creator><creator>Rodríguez, Maria José Requena</creator><creator>de Marcos, Nieves Somolinos</creator><creator>Font, Patricia</creator><general>Springer Healthcare Communications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201103</creationdate><title>Acute myeloblastic leukemia</title><author>Molina, Carmen Avellaneda ; Rodríguez, Maria José Requena ; de Marcos, Nieves Somolinos ; Font, Patricia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2583-d3afc5a4ede8e785dcc09ccaf702bddc85a80175ae12fef299d4ecd74f5c2f9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Azacitidine - administration & dosage</topic><topic>Azacitidine - adverse effects</topic><topic>Bone Marrow - pathology</topic><topic>Bone Marrow - physiopathology</topic><topic>Cardiology</topic><topic>Clinical Cases</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Hypersensitivity - etiology</topic><topic>Endocrinology</topic><topic>Erythema Nodosum - etiology</topic><topic>Female</topic><topic>Health technology assessment</topic><topic>Hematopoiesis - drug effects</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - etiology</topic><topic>Leukemia, Myeloid, Acute - pathology</topic><topic>Leukemia, Myeloid, Acute - physiopathology</topic><topic>Lung Diseases, Fungal - etiology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Myelodysplastic Syndromes - complications</topic><topic>Myelodysplastic Syndromes - drug therapy</topic><topic>Myelodysplastic Syndromes - pathology</topic><topic>Myelodysplastic Syndromes - physiopathology</topic><topic>Oncology</topic><topic>Pharmacology/Toxicology</topic><topic>Remission Induction</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Molina, Carmen Avellaneda</creatorcontrib><creatorcontrib>Rodríguez, Maria José Requena</creatorcontrib><creatorcontrib>de Marcos, Nieves Somolinos</creatorcontrib><creatorcontrib>Font, Patricia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Molina, Carmen Avellaneda</au><au>Rodríguez, Maria José Requena</au><au>de Marcos, Nieves Somolinos</au><au>Font, Patricia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute myeloblastic leukemia</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Therapy</stitle><addtitle>Adv Ther</addtitle><date>2011-03</date><risdate>2011</risdate><volume>28</volume><issue>Suppl 3</issue><spage>10</spage><epage>16</epage><pages>10-16</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Myelodysplastic syndromes (MDS) are a group of clonal cell disorders characterized by maturation defects, resulting in ineffective hematopoiesis. They often transform to acute myeloblastic leukemia (AML), which is difficult to treat and carries a dismal prognosis. Azacitidine is a hypomethylating agent approved for the treatment of patients with MDS, including AML with 20% to 30% bone marrow blasts, according to World Health Organization classification. The three patient cases presented in this paper exemplify the spectrum of antitumor activity and toxicity of azactidine in patients where MDS transformed to AML.</abstract><cop>Heidelberg</cop><pub>Springer Healthcare Communications</pub><pmid>21431629</pmid><doi>10.1007/s12325-010-0109-3</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0741-238X |
| ispartof | Advances in therapy, 2011-03, Vol.28 (Suppl 3), p.10-16 |
| issn | 0741-238X 1865-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_859756376 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Azacitidine - administration & dosage Azacitidine - adverse effects Bone Marrow - pathology Bone Marrow - physiopathology Cardiology Clinical Cases Dose-Response Relationship, Drug Drug Hypersensitivity - etiology Endocrinology Erythema Nodosum - etiology Female Health technology assessment Hematopoiesis - drug effects Humans Internal Medicine Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - etiology Leukemia, Myeloid, Acute - pathology Leukemia, Myeloid, Acute - physiopathology Lung Diseases, Fungal - etiology Male Medicine Medicine & Public Health Middle Aged Myelodysplastic Syndromes - complications Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - pathology Myelodysplastic Syndromes - physiopathology Oncology Pharmacology/Toxicology Remission Induction Rheumatology |
| title | Acute myeloblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T20%3A56%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20myeloblastic%20leukemia&rft.jtitle=Advances%20in%20therapy&rft.au=Molina,%20Carmen%20Avellaneda&rft.date=2011-03&rft.volume=28&rft.issue=Suppl%203&rft.spage=10&rft.epage=16&rft.pages=10-16&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-010-0109-3&rft_dat=%3Cproquest_cross%3E859756376%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=859756376&rft_id=info:pmid/21431629&rfr_iscdi=true |